ADVA unveils new DCI OLS for the 400ZR era
30.3.2021 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its new FSP 3000 data center interconnect (DCI) open line system (OLS) specifically designed for 400ZR technologies. The new DCI OLS addresses the most urgent challenges for network operators by enabling commercial deployments of DCI infrastructure based on 400ZR. These high-density, cost-effective, open solutions that are optimized for point-to-point applications up to 120km will be key to rapidly expanding DCI capacity to meet soaring data demand. Currently undergoing customer testing and evaluation, the ADVA DCI OLS has demonstrated seamless interoperability with 400ZR pluggable transceivers. The solution is fully compliant and even outperforms the 400ZR standard. What’s more, with data center-compatible open APIs, it can be directly integrated into SDN environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210330005055/en/
ADVA’s new DCI OLS will be pivotal to unlocking the full potential of 400ZR (Photo: Business Wire)
“Today we’re announcing a major milestone for open, high-capacity data center networks. The launch of our new DCI OLS will be key for operators. It provides the missing link to real-world deployments of open infrastructure built with 400ZR interfaces,” said Christoph Glingener, CTO, ADVA. “Our pedigree in the DCI space is second to none. We were the original DCI company, enabling Fortune 500 companies around the globe to harness the cloud with best-in-breed solutions. For more than 25 years, our innovation has helped the industry evolve. Now we’re giving large-scale DCI providers what they need to move forward. Our next-generation FSP 3000 DCI OLS offers a way to inject ultra-high capacity while reducing total cost of ownership and operational complexity. What’s more, the ADVA FSP 3000 DCI OLS solution is designed to optimize performance with 400ZR-compliant optics from any vendor.”
The ADVA FSP 3000 DCI OLS is fully compliant with the OIF’s implementation agreement for 400ZR coherent optical interfaces. Optimized for amplified 400Gbit/s DWDM links with reaches up to 120km at 75GHz or 100GHz channel spacing, the solution exceeds all 400ZR performance specifications. It’s also compatible with OpenZR+ interfaces, which expand the application area to DCI applications with distances far beyond 120km. With its open interfaces, the ADVA DCI OLS ensures seamless integration with third-party transceivers and enables network operators to deploy best-of-breed technology. A high level of functional integration minimizes fiber cabling and provides simplified, automated and rapid turnup for optimal performance. The ADVA FSP 3000 DCI OLS integrates multiple diagnostic tools, including built-in OTDR for the monitoring of all fibers and built-in optical channel monitoring. These automated diagnostic capabilities significantly reduce operating costs and improve repair time.
“Omdia is projecting a significant market take-up for 400ZR pluggable technology. 400ZR has many appealing attributes, including multi-vendor interoperability, appealing cost per bit, and a small form factor with low power consumption. Additionally, 400ZR will be practically deployable in switch/routing platforms, enabling the realization of a decades-long service provider dream,” commented Ian Redpath, practice leader, transport networks and components, Omdia. “ADVA has a proven co-development track record in supporting open and innovative DCI solutions. With its new DCI OLS, ADVA is ideally positioned to take the open line system concept to the next level, interworking directly with 400ZR. And with open API support, ADVA will ensure tight integration with cloud and network provider SDN orchestration and control systems.”
Watch this video for more information on the new DCI OLS: https://youtu.be/8zI3E46oMBo.
Further details are also available in these slides: https://adva.li/dci-ols-400zr-slides.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005055/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
